Agios Pharmaceuticals, Inc.
AGIO · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Operating Activities | – | – | – | – |
| Net Income | $673,725 | -$352,088 | -$231,801 | -$356,510 |
| Dep. & Amort. | $5,653 | $6,623 | $8,564 | $9,240 |
| Deferred Tax | $0 | $0 | $0 | $0 |
| Stock-Based Comp. | $42,847 | $44,766 | $49,296 | $53,508 |
| Change in WC | -$19,768 | -$19,057 | -$16,433 | -$36,822 |
| Other Non-Cash | -$1,092,298 | $23,694 | -$119,104 | -$76,736 |
| Operating Cash Flow | -$389,841 | -$296,062 | -$309,478 | -$407,320 |
| Investing Activities | – | – | – | – |
| PP&E Inv. | -$1,685 | -$999 | -$4,881 | -$5,741 |
| Net Acquisitions | $40 | $0 | $132,748 | $0 |
| Inv. Purchases | -$1,542,433 | -$417,930 | -$1,030,781 | -$1,378,221 |
| Inv. Sales/Matur. | $818,383 | $674,679 | $1,146,175 | $829,804 |
| Other Inv. Act. | $1,089,136 | -$16,175 | $0 | $1,802,936 |
| Investing Cash Flow | $363,441 | $239,575 | $243,261 | $1,248,778 |
| Financing Activities | – | – | – | – |
| Debt Repay. | $0 | $0 | -$331 | -$578 |
| Stock Issued | $14,442 | $5,433 | $2,681 | $0 |
| Stock Repurch. | $0 | $0 | $0 | -$802,486 |
| Dividends Paid | $0 | $0 | $0 | $0 |
| Other Fin. Act. | $0 | $0 | $0 | $37,296 |
| Financing Cash Flow | $14,442 | $5,433 | $2,350 | -$765,768 |
| Forex Effect | $0 | $0 | $0 | $0 |
| Net Chg. in Cash | -$11,958 | -$51,054 | -$63,867 | $75,690 |
| Supplemental Information | – | – | – | – |
| Beg. Cash | $88,205 | $139,259 | $203,126 | $127,436 |
| End Cash | $76,247 | $88,205 | $139,259 | $203,126 |
| Free Cash Flow | -$391,526 | -$297,061 | -$314,359 | -$413,061 |